Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
This is a paid press release. Contact the press release distributor directly with any inquiries.
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
BillionToOne, Inc.
Tue, February 17, 2026 at 10:05 PM GMT+9 1 min read
In this article:
BLLN
-1.20%
BillionToOne, Inc.
MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) – BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
To participate in the conference call, please register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast will be available on the “Events” page of BillionToOne’s investor relations website at
About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company’s patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.
Investor Contact
ir@billiontoone.com
Media Contact
billiontoone@moxiegrouppr.com
Terms and Privacy Policy
Privacy Dashboard
More Info